Core Viewpoint - Cousins Properties (CUZ) has experienced a significant decline of 19% over the past four weeks, but it is now positioned for a potential trend reversal as it is in oversold territory, with analysts expecting better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - CUZ has an RSI reading of 22.72, suggesting that the heavy selling pressure may be exhausting, indicating a potential bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for CUZ will improve, leading to a 0.3% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [7]. - CUZ holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].

Core Viewpoint - Analysts expect CF Industries to report quarterly earnings of $2.50 per share, reflecting a year-over-year increase of 32.3%, with revenues projected at $1.79 billion, up 17.3% from the previous year [1] Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock performance [2] Key Metrics Forecast - Analysts project 'Net Sales- Ammonia' at $570.71 million, indicating a year-over-year change of -0.2% [4] - 'Net Sales- Granular Urea' is expected to reach $423.03 million, reflecting a change of +21.6% from the prior year [4] - 'Net Sales- UAN (urea ammonium nitrate)' is forecasted at $560.37 million, suggesting a year-over-year increase of +50.6% [4] Sales Volume Estimates - 'Sales volume by product - Ammonia' is estimated at 1165 thousand tons, down from 1240 thousand tons year-over-year [5] - 'Sales volume by product - Granular Urea' is projected at 1022 thousand tons, up from 1002 thousand tons in the same quarter last year [6] - 'Sales volume by product - UAN' is expected to reach 1694 thousand tons, compared to 1613 thousand tons year-over-year [6] Average Selling Price - The average selling price per ton of 'Granular Urea' is estimated at $412.49, up from $347.00 a year ago [7] - The average selling price per ton of 'Ammonia' is projected at $485.54, compared to $461.00 in the same quarter last year [7] Other Sales Volume - 'Sales volume by product - Other Sales volume' is expected to be 581 thousand tons, compared to 535 thousand tons year-over-year [8] - 'Sales volume by product - AN (ammonium nitrate)' is projected at 244 thousand tons, down from 357 thousand tons in the same quarter last year [8] Stock Performance - Over the past month, shares of CF have returned +8.7%, while the Zacks S&P 500 composite has changed by -2% [9] - CF currently holds a Zacks Rank 3 (Hold), indicating that its performance may align with the overall market in the near future [9]

Core Insights - Deere (DE) is expected to report quarterly earnings of $1.92 per share, reflecting a decline of 39.8% year-over-year, while revenues are forecasted to reach $7.6 billion, an increase of 11.7% year-over-year [1] Earnings Estimates - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock performance [2] Revenue Projections - Analysts estimate 'Net Sales and Revenues- Production & precision ag net sales' at $3.05 billion, indicating a decrease of 0.6% from the prior-year quarter [4] - 'Net Sales and Revenues- Equipment Operations- Net sales' is projected to reach $7.58 billion, suggesting an increase of 11.3% year-over-year [4] - 'Net Sales and Revenues- Small ag & turf net sales' is expected to be $2.16 billion, reflecting a growth of 23.7% from the year-ago quarter [5] - 'Net Sales and Revenues- Other revenues' is estimated at $223.12 million, indicating a decline of 2.6% from the prior-year quarter [5] Financial Services Revenue - The consensus estimate for 'Net Sales and Revenues- Financial services revenues' stands at $1.38 billion, suggesting a decrease of 5.9% year-over-year [6] - 'Net Sales and Revenues- Financial services- Total' is projected at $1.49 billion, indicating a year-over-year change of -5.6% [6] - 'Net Sales and Revenues- Financial services- Other Income' is expected to reach $118.14 million, reflecting a slight increase of 0.1% from the prior-year quarter [7] - 'Net Sales and Revenues- Financial services- Finance and Interest Income' is estimated at $1.37 billion, indicating a year-over-year decline of 6% [7] Overall Performance - Analysts forecast 'Net Sales and Revenues- Net sales' to reach $7.55 billion, suggesting a change of +10.9% from the year-ago quarter [8] - 'Net Sales and Revenues- Equipment Operations- Finance and interest income' is projected at $109.94 million, indicating a slight decline of 0.1% from the prior-year quarter [8] - The consensus for 'Net Sales and Revenues- Equipment Operations- Other income' is $196.47 million, reflecting a year-over-year change of -2.7% [9] - Over the past month, Deere shares have increased by 16.1%, contrasting with the Zacks S&P 500 composite's decline of 2% [9]

分组1 - Wall Street analysts expect Reliance to report quarterly earnings of $2.80 per share, reflecting a year-over-year increase of 26.1% [1] - Revenues are anticipated to reach $3.38 billion, which is an 8.2% increase from the same quarter last year [1] - The consensus EPS estimate has been revised upward by 0.3% in the past 30 days, indicating a reassessment of initial estimates by analysts [1] 分组2 - Analysts project 'Net Sales- Carbon Steel' to be $1.84 billion, representing a 9.5% increase year-over-year [4] - 'Net Sales- Alloy' is expected to reach $146.15 million, indicating a 2.1% increase from the prior year [4] - 'Net Sales- Stainless Steel' is forecasted at $476.93 million, showing a 0.8% increase compared to the previous year [4] 分组3 - The estimate for 'Net Sales- Aluminium' is $587.58 million, suggesting a 10% year-over-year change [5] - The average selling price per ton sold is projected to be $2275.56, up from $2170.00 in the same quarter last year [5] - The consensus estimate for 'Shipments (Tons sold)' stands at 1.51 million, compared to 1.44 million in the year-ago quarter [5] 分组4 - Analysts expect 'Tons Sold - Aluminium' to reach 77.25 thousand, an increase from 75.80 thousand reported last year [6] - The average prediction for 'Tons Sold - Stainless Steel' is 70.95 thousand, up from 67.70 thousand in the same quarter last year [6] - 'Tons Sold - Alloy' is estimated at 28.06 thousand, compared to 27.80 thousand from the previous year [7] 分组5 - 'Tons Sold - Carbon Steel' is projected to be 1.26 million, an increase from 1.19 million reported last year [7] - Reliance shares have increased by 14.2% in the past month, contrasting with the Zacks S&P 500 composite's decline of 0.3% [7] - Reliance holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [7]

Core Viewpoint - Analysts project that Energy Transfer LP (ET) will report quarterly earnings of $0.34 per share, reflecting a year-over-year increase of 17.2%, with revenues expected to reach $26.02 billion, a 33.2% increase from the same quarter last year [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate for the quarter has been revised upward by 4.8%, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Key Metrics Forecast - Analysts expect 'Midstream - Gathered volumes' to be 21,570 billion British thermal units per day, up from 20,690 billion British thermal units per day year-over-year [5]. - The forecast for 'Midstream - NGLs produced' is 1,160.76 thousand barrels of oil per day, compared to 1,134.00 thousand barrels of oil per day in the same quarter last year [5]. - 'Midstream - Equity NGLs' is projected to reach 64.91 thousand barrels of oil per day, an increase from 59.00 thousand barrels of oil per day year-over-year [6]. - 'NGL and Refined Products Transportation and Services - NGL and refined products terminal volumes' are expected to be 1,674.22 thousand barrels of oil per day, up from 1,465.00 thousand barrels of oil per day year-over-year [6]. - 'NGL and Refined Products Transportation and Services - NGL fractionation volumes' are forecasted at 1,139.30 thousand barrels of oil per day, slightly down from 1,141.00 thousand barrels of oil per day in the same quarter last year [7]. - The estimate for 'NGL and Refined Products Transportation and Services - Refined products transportation volumes' stands at 593.50 thousand barrels of oil per day, compared to 570.00 thousand barrels of oil per day year-over-year [8]. - 'NGL and Refined Products Transportation and Services - NGL transportation volumes' are expected to be 2,361.50 thousand barrels of oil per day, up from 2,262.00 thousand barrels of oil per day in the same quarter last year [9]. Adjusted EBITDA Projections - 'Adjusted EBITDA- Intrastate transportation and storage' is projected to reach $271.38 million, compared to $263.00 million in the same quarter last year [10]. - 'Adjusted EBITDA- Interstate transportation and storage' is expected to be $502.98 million, up from $493.00 million year-over-year [10]. - 'Adjusted EBITDA- Crude oil transportation and services' is forecasted at $746.73 million, down from $760.00 million in the same quarter last year [11]. - 'Adjusted EBITDA- NGL and refined products transportation and services' is estimated to reach $1.10 billion, compared to $1.11 billion year-over-year [12]. - The estimated 'Adjusted EBITDA- Midstream' is $810.34 million, up from $705.00 million in the same quarter last year [12]. Stock Performance - Over the past month, Energy Transfer LP shares have returned +4.1%, while the Zacks S&P 500 composite has changed by -0.3% [12].

Core Viewpoint - Wall Street analysts predict that Analog Devices (ADI) will report quarterly earnings of $2.30 per share, reflecting a year-over-year increase of 41.1%, with revenues expected to reach $3.12 billion, marking a 28.7% increase compared to the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has been revised upward by 1.2% in the past 30 days, indicating a reassessment of initial estimates by covering analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections by End Market - Revenue from the Consumer end market is forecasted to reach $359.11 million, representing an 11.2% year-over-year increase [5]. - Revenue from the Communications end market is expected to be $423.96 million, indicating a significant 46.3% increase from the prior-year quarter [5]. - The Automotive end market's revenue consensus stands at $801.93 million, reflecting a 9.5% increase year-over-year [5]. - Revenue from the Industrial end market is projected at $1.50 billion, showing a year-over-year change of 38.8% [6]. Stock Performance - Analog Devices shares have increased by 13.1% over the past month, contrasting with the Zacks S&P 500 composite's decline of 0.3%, suggesting that ADI is expected to outperform the overall market in the near term [6].

Core Insights - Nordson (NDSN) is expected to report quarterly earnings of $2.36 per share, reflecting a 14.6% increase year-over-year, with revenues forecasted at $650.83 million, a 5.8% increase from the previous year [1] Earnings Estimates - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock performance [2] - Analysts have maintained the consensus EPS estimate for Nordson over the last 30 days, indicating stability in their assessments [1] Revenue Forecasts - Analysts predict 'Net Sales- Industrial Precision Solutions' to be $308.50 million, a year-over-year increase of 2.7% [4] - 'Net Sales- Advanced Technology Solutions' is expected to reach $138.00 million, reflecting a 13.7% increase from the same quarter last year [4] - 'Net Sales- Medical and Fluid Solutions' is forecasted at $204.00 million, indicating a 5.4% increase year-over-year [4] Operating Profit Estimates - 'Operating profit (loss)- Advanced Technology Solutions' is projected to be $24.00 million, up from $18.12 million in the same quarter last year [5] - 'Operating profit (loss)- Medical and Fluid Solutions' is expected to reach $58.50 million, compared to $40.94 million a year ago [5] - 'Operating profit (loss)- Industrial Precision Solutions' is estimated at $102.00 million, an increase from $95.71 million in the previous year [6] Stock Performance - Over the past month, Nordson shares have increased by 10.5%, while the Zacks S&P 500 composite has decreased by 0.3%, indicating strong relative performance [6] - Nordson holds a Zacks Rank 3 (Hold), suggesting that its performance is likely to align with the overall market in the near term [6]

Core Viewpoint - Global Payments (GPN) is expected to report quarterly earnings of $3.18 per share, a 7.8% increase year-over-year, with revenues projected at $2.32 billion, reflecting a 1.4% year-over-year increase [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate for the quarter has been revised upward by 0.3%, indicating analysts' reassessment of their initial forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts project 'Non-GAAP Revenues - Merchant Solutions' to reach $1.77 billion, indicating a year-over-year change of +0.3% [5]. - 'Non-GAAP Revenues - Issuer Solutions' is estimated to be $565.94 million, reflecting a +4.4% change from the previous year [5]. - 'Revenues - Merchant Solutions' are predicted to be $1.93 billion, suggesting a +2.1% year-over-year change [5]. Operating Income Estimates - 'Non-GAAP Operating Income - Merchant Solutions' is expected to be $880.59 million, compared to $852.03 million reported in the same quarter last year [6]. - 'Non-GAAP Operating Income - Issuer Solutions' is projected at $269.31 million, up from $254.44 million in the previous year [6]. - The consensus for 'Operating Income - Merchant Solutions' is $674.05 million, compared to $652.41 million reported in the same quarter last year [7]. Stock Performance - Shares of Global Payments have decreased by -6.8% over the past month, contrasting with a -0.3% change in the Zacks S&P 500 composite [7]. - With a Zacks Rank 2 (Buy), GPN is anticipated to outperform the overall market in the near future [7].

Core Viewpoint - Leidos (LDOS) is expected to report quarterly earnings of $2.57 per share, an increase of 8.4% year-over-year, while revenues are forecasted to decline by 2.6% to $4.25 billion [1] Earnings Estimates - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock performance [2] Revenue Projections - Analysts forecast 'Revenues- Health & Civil' to reach $1.26 billion, indicating a year-over-year decrease of 4.8% [3] - 'Revenues- National Security and Digital' are projected to be $1.90 billion, reflecting a slight increase of 0.5% year-over-year [4] - 'Revenues- Commercial & International' are expected to be $568.93 million, down 5.8% from the prior-year quarter [4] - 'Revenues- Defense Systems' are estimated at $527.48 million, a decrease of 2.1% from the year-ago quarter [4] Operating Income Estimates - The consensus estimate for 'Non-GAAP operating income (loss)- Defense Systems' is $47.23 million, compared to $19.00 million from the previous year [5] - 'Operating income (loss)- National Security & Digital' is expected to be $180.05 million, up from $175.00 million in the same quarter last year [5] - 'Non-GAAP operating income (loss)- Health & Civil' is projected at $273.68 million, down from $287.00 million year-over-year [6] - 'Non-GAAP operating income (loss)- Commercial & International' is estimated at $44.62 million, compared to $48.00 million last year [7] - 'Operating income (loss)- Health & Civil' is expected to be $270.49 million, down from $279.00 million year-over-year [7] - 'Operating income (loss)- Commercial & International' is projected at $40.48 million, slightly up from $40.00 million in the same quarter last year [8] Stock Performance - Shares of Leidos have shown a return of -0.6% over the past month, compared to a -0.3% change in the Zacks S&P 500 composite [8] - Leidos holds a Zacks Rank 3 (Hold), indicating it is expected to mirror overall market performance in the near future [8]

Core Insights - Royalty Pharma (RPRX) is expected to report quarterly earnings of $1.33 per share, reflecting a 15.7% increase year-over-year, with revenues projected at $824.89 million, an 11.2% increase from the previous year [1] Earnings Projections - Analysts have not revised the consensus EPS estimate for the quarter in the past 30 days, indicating stability in expectations [1] - The importance of earnings estimate revisions is highlighted as they are a critical gauge for predicting investor behavior [2] Key Metrics Projections - Analysts predict 'Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise' will reach $230.74 million, a decrease of 2.6% year-over-year [4] - 'Portfolio Receipts- Royalty Receipts- Products- Tysabri' is expected to reach $64.04 million, reflecting a 5% increase from the prior year [4] - 'Portfolio Receipts- Royalty Receipts- Products- Imbruvica' is projected at $41.09 million, indicating a 10.7% decrease year-over-year [5] - 'Portfolio Receipts- Royalty Receipts- Products- Xtandi' is expected to reach $49.32 million, a 7.2% increase from the previous year [5] - 'Portfolio Receipts- Royalty Receipts- Products- Promacta' is projected at $22.16 million, showing a significant decrease of 49.6% year-over-year [6] - 'Portfolio Receipts- Royalty Receipts- Products- Tremfya' is expected to reach $57.64 million, reflecting a 47.8% increase [6] - 'Portfolio Receipts- Milestones and other contractual receipts' is estimated at $11.40 million, a decrease of 12.4% year-over-year [7] - 'Portfolio Receipts- Royalty Receipts- Products- Evrysdi' is projected at $58.82 million, indicating a 5% increase [7] - 'Portfolio Receipts- Royalty Receipts- Products- Trodelvy' is expected to reach $11.79 million, a 7.1% increase from the previous year [8] - The total for 'Portfolio Receipts- Royalty Receipts- Products' is projected at $813.50 million, reflecting an 11.6% increase year-over-year [8] - 'Portfolio Receipts- Royalty Receipts- Products- Trelegy' is estimated at $93.70 million, indicating a 26.6% increase [9] - 'Portfolio Receipts- Royalty Receipts- Products- Spinraza' is projected at $13.37 million, suggesting a 10.9% decrease year-over-year [9] Stock Performance - Over the past month, shares of Royalty Pharma have returned +9.4%, while the Zacks S&P 500 composite has shown no change [9]